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Abstract
Background: There is an insufficient number of reliable prognostic and response predictive biomarkers in
colorectal cancer (CRC) management. In a previous study, we found that high tumour tissue expression of tumour-
associated trypsin inhibitor (TATI) correlated with liver metastasis and an impaired prognosis in CRC. The aim of this
study was to investigate the prognostic validity of serum TATI (s-TATI) in CRC. We further assessed the prognostic
value of carcino-embryonic antigen in serum (s-CEA) and the interrelationship between s-TATI and TATI in tissue
(t-TATI).
Methods: Using an immunofluorometric assay, s-TATI levels were analysed in 334 preoperatively collected serum
samples from patients with CRC. Spearman’s Rho and Chi-square test were used for analysis of correlations
between s-TATI and clinicopathological parameters, s-CEA and t-TATI. Kaplan-Meier analysis and Cox uni- and
multivariate regression analysis were used to estimate disease free survival (DFS) and overall survival (OS) according
to quartiles of s-TATI and cut-offs derived from ROC-analysis of s-TATI and s-CEA.
Results: Increased levels of s-TATI were associated with a reduced DFS (HR = 2.00; 95% CI 1.40-2.84, P < 0.001) and
OS (HR = 2.40; 95% CI 1.74-3.33, P < 0.001). (HR = 2.89; 95% CI 1.96-4.25). This association remained significant in
multivariate analysis. The association for OS remained significant in multivariate analysis (HR = 1.51; 95% CI 1.03-
2.22, P = 0.034 for DFS and HR = 1.78; 95% CI 1.25-2.53, P = 0.001 for OS). There was no significant association
between s-TATI and t-TATI. The prognostic value of s-CEA was also evident, but somewhat weaker than for s-TATI.
Conclusions: High preoperative s-TATI levels predict a poor prognosis in patients with CRC, and the prognostic
value is independent of established prognostic parameters and t-TATI expression. These data suggest that s-TATI
might be a useful marker for prognostic stratification in CRC.
Background
Colorectal cancer (CRC) is one of the most common
forms of cancer worldwide with approximately 1 million
new cases detected every year [1]. Early detection, ade-
quate surgical excision and optimal adjuvant treatment
are of critical importance for outcome. Although several
prognostic and predictive CRC biomarkers have been
proposed [2], serum carcino-embryonic antigen (s-CEA)
is currently the only accepted marker incorporated into
clinical practice. S-CEA is used for early detection of
metastasis during follow-up of patients with stage II and
III disease and for monitoring response to adjuvant
treatment in stage IV disease.
In a previous study by our group, we found that a
high expression of tumour-associated trypsin inhibitor
(TATI; synonymous to pancreatic secretory trypsin inhi-
bitor, PSTI, and serine protease inhibitor Kazal type 1,
SPINK1) in tumour tissue (t-TATI) was associated with
an increased risk of metachronous liver metastasis and
an impaired prognosis in CRC patients [3]. These find-
ings are supported by in vitro data, demonstrating that
TATI promotes invasiveness of CRC cells [4].
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Several studies have found s-TATI to be of potential
prognostic value in ovarian cancer [5,6], a good serum
marker for monitoring [7] and prognosis [8] of bladder
cancer, prognosis of renal cancer [9] and more accurate
than CEA, carbohydrate antigen (CA) 15-3, CA 125 and
CA 19-9 in post-operative follow up of renal cancer
patients [10]. Previous studies on s-TATI in various
cancer forms have been performed on rather small
cohorts with diverging conclusions regarding its prog-
nostic value. In a study from 1991, s-TATI was found to
be a good predictor of liver metastasis in CRC and
breast cancer [11]. Satake et al found elevated s-TATI
concentrations in CRC patients, but the results were not
considered to be of sufficient diagnostic value for clini-
cal use [12]. In a study on 62 CRC patients, Pasanen et
al found s-TATI to be a useful biomarker for staging of
CRC, however less useful than s-CEA [13]. Similar
results were obtained in another study comprising 53
CRC patients [14]. Solakidi et al found s-TATI to be a
useful complementary biomarker for diagnosing and
monitoring of gastrointestinal malignancies, having a
higher sensitivity than s-CEA [15].
Three main mechanisms have been proposed to cause
increased levels of TATI in serum; leakage from
tumour-derived TATI into the circulation and as a
response to tissue destruction and inflammation [16]. A
transitory elevation of s-TATI levels have been found
after surgery, suggesting that TATI may behave as an
acute phase protein [14,17]. Elevated levels of s-TATI
can also be detected temporarily in some non-malignant
conditions, especially in pancreatitis [18], and in severe
inflammatory diseases, injuries, and sepsis [12,19].
The purpose of the present study was to examine the
prognostic value of s-TATI in a cohort of 324 prospec-
tively collected CRC patients, including 308 cases pre-
viously analysed for t-TATI [3]. Furthermore, the
prognostic value of s-CEA was assessed, as well as the
association between s-TATI and t-TATI.
Methods
Patients
The original cohort consisted of 337 prospectively col-
lected patients undergoing surgery for CRC at the Cen-
tral District Hospital in Västerås, Sweden, between June
2000 and December 2003. Tumour tissue for construc-
tion of tissue microarrays (TMA) was available from 320
(95%) patients [3]. Pretreatment serum samples were
available from 325 patients and s-TATI could be ana-
lysed in 324 (96%). Both tissue and serum data were
available from 308 patients (91%), Serum data was avail-
able for 275 (82%) curatively treated patients.
Median follow-up time for surviving patients with
samples available for s-TATI analysis was 6 (range 4-8)
years. Recurrent disease was reported in 54 (19%) of
curatively treated patients while 119 (37%) patients died
during the study period. Preoperative radiotherapy (RT)
was given to 84/108 patients with rectal cancer. All
patients under 75 years of age with stage III colon can-
cer (n = 36) and 22 of 29 rectal cancer patients received
adjuvant chemotherapy as well as some patients with
high risk (T4, low differentiation) stage II disease (13/
71). Palliative chemotherapy was given to 23 of 27
patients <75 years with stage IV disease.
Ethical approval for the study was obtained from the
Ethic’s committee at Uppsala University (ref no 00-001),
whereby all patients gave their informed consent for
participation in the study.
Immunofluorometric assay of s-TATI
Serum samples were drawn prior to surgical treatment
and stored at -70°C until analysis. The samples were
analysed using a time-resolved immunofluorometric
assay [20]. MAb 6E8 was used as a capture antibody for
TATI and a europium (Eu) labelled antibody 11B3 was
used as a tracer. Fluorescence was measured with a
1234 Victor 2 time-resolved fluorometer (Wallac,
Turku, Finland. The lower limit of detection for TATI
is 0.1 μg/l and the measuring range 0.5-90 μg/l.
S-CEA
CEA in serum was determined by ELISA with commer-
cially available MTPL-EIA kit (RE59101, IBL IMMUNO
BIOLOGICAL LABORATORIES; http://www.ibl-ham-
burg.com). According to the manufacturer’s instructions,
the assay has a detection limit of 1 μg/l and a measuring
range of 5-75 μg/l.
Statistics
Correlations between s-TATI and clinicopathological
characteristics were calculated using Spearman’s Rho-
test and Chi-square test. Kaplan-Meier analysis and log-
rank test were used to estimate the relationship between
different strata of s-TATI levels, disease free survival
(DFS) and overall survival (OS). Endpoints for DFS and
OS were defined as recommended by Punt et al [20].
Curatively treated patients were defined as patients with
Stage I-III disease and microscopically free resection
margins (R0). All observations were censored at the end
of the study period (15th November 2008). The Kolmo-
gorov-Smirnov test was used to verify a normal or
skewed distribution. Bivariate correlation analysis
between s-TATI and s-CEA was performed. Optimal
cut-off values were determined using a receiver operat-
ing characteristic (ROC) analysis including all patients
in relation to OS. The TATI concentration at the ROC
curve’s closest point to the top of Y-axis (1.0) was used
as cut-off. Quartile-concentration thresholds for the
whole group were used for comparison. A Cox
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proportional hazards model was used for estimation of
hazard ratio (HR) in both uni- and multivariate analysis
after adjustment for age, gender, disease stage, differen-
tiation grade, lymphatic or vascular invasion, s-CEA, s-
TATI and t-TATI. Statistical analyses were carried out
using the Statistical Package for Social Sciences, SPSS
16.0 package (SPSS Inc, Chicago, Ill) while ROC curve
analysis and comparison of ROC curves and optimal
cut-off calculation was performed using MedCalc statis-
tical software 11.2 (MedCalc Inc., Mariakerke, Belgium).
A P-value less than 0.05 was considered significant.
Results
Distribution of TATI in serum
The range of s-TATI concentrations in CRC patients
was 4.4 μg/l to 169 μg/l (mean; 23.5 μg/l, median; 13.5
μg/l). The distribution was skewed and this was verified
by Kolmogorov-Smirnov’s test (P < 0.001). Based on
ROC analysis the optimal cut-off was set to 15.59 μg/l.
The AUC value for prediction of OS (Figure 1A) was
0.684 for s-TATI (P < 0.001) and 0.644 for s-CEA (P <
0.001). In curatively treated patients the AUC (Figure
1B) for s-TATI was 0.706 (P < 0.001) and 0.612 for s-
CEA (P = 0.002) (Figure 1B). The range of the s-TATI
quartiles were 4.346-10.432, 10.433-13.544, 13.545-
22.039, 22.040-168.570 μg/l.
Correlation between s-TATI and t-TATI
There was no significant association between s-TATI
and t-TATI (continuous percentage of positive cells)
(Spearman’s Rho = 0.031, P = 0.591). This was also evi-
dent in separate analysis of curatively treated patients,
different disease stages as well as colonic versus rectal
cancer (data not shown).
Correlations between s-TATI and clinicopathological
characteristics
Higher s-TATI levels were significantly associated with
M stage (P = 0.02), but not with TNM stage, lymph
node (N) or tumour (T) stage (Figure 2). As shown in
table 1, s-TATI was significantly associated with higher
age at diagnosis (P < 0.001) and right-sided tumour
location (P < 0.001). Patients with cancer in the colon
had significantly higher s-TATI levels than rectal cancer
patients (P = 0.001). Notably, preoperative RT had been
given to 84/107 (79%) rectal cancer patients in the
evaluated cohort and in patients who had received
preoperative RT (n = 85, all but one with rectal cancer),
s-TATI levels were significantly lower than in patients
who had not (P = 0.001). There was no significant dif-
ference in s-TATI levels between left-sided colonic
tumours and rectal cancers (data not shown). In con-
trast to s-TATI, s-CEA levels did not differ significantly
in relation to tumour location or preoperative RT and
neither did t-TATI (data not shown).
Prognostic value of s-TATI and correlation to distant
metastases
In ROC analysis the AUC values of both s-CEA and
s-TATI ROC correlated significantly with OS (s-TATI;
P < 0.001, s-CEA; P < 0.001) (Figure 1A). This was also
the case in curatively treated patients (s-TATI;
P < 0.001, s-CEA; P = 0.002) (Figure 1B). The difference
in AUC values between s-TATI and s-CEA was signifi-
cant in curatively treated patients (P = 0.0441) but not
in the whole cohort (P = 0.346) (Figure 1B).
Analysis of DFS and OS was performed both accord-
ing to the dichotomized cut-off and according to s-
TATI quartiles. Both approaches revealed a significant
association (P < 0.001) between high concentrations of
s-TATI and a shorter DFS and OS (Figure 3). Cox uni-
variate analysis confirmed the association between s-
TATI and DFS (HR = 2.00; 95% CI 1.40-2.84, P < 0.001)
and OS (HR = 2.40; 95% CI 1.74-3.33, P < 0.001) (Table
2) and this association remained significant in multivari-
ate analysis adjusted for age, gender, disease stage, dif-
ferentiation grade, lymphatic or vascular invasion,
s-CEA, and t-TATI (HR = 1.51; 95% CI 1.03-2.22,
P = 0.034 for DFS and HR = 1.78; 95% CI 1.25-2.53,
P = 0.001 for OS). Notably, when adjusted for s-TATI,
t-TATI was an independent prognostic factor for DFS
but not for OS (Table 2). The prognostic value of
s-CEA analysed using ROC cut-off was more significant
for DFS, but less significant than s-TATI as a predictor
of OS (Table 2).
The adverse impact of high s-TATI levels on OS was
retained also when analyzed separately for cases with
stage II and III disease respectively (Figure 4). This was
confirmed in Cox univariate analysis (HR = 2.58; 95%
CI 1.39-4.79, P = 0.003 for Stage II and HR = 2.61; 95%
CI 1.49-4.59, P = 0.001 for Stage III) and remained sig-
nificant in multivariate analysis adjusted for age, gender,
differentiation grade, lymphatic or vascular invasion,
s-CEA and t-TATI (HR = 2.06; 95% CI 1.08-3.93,
P = 0.028 for Stage II and HR = 2.24; 95% CI 1.19-4.21,
P = 0.013 for Stage III patients). While a high s-CEA
concentration was a significant predictor of reduced OS
in patients with Stage II disease in both univariate (HR
= 2.17; 95% CI 1.15-4.10, P = 0.017) and multivariate
analysis (HR = 2.00; 95% CI 1.04-3.87, P = 0.039), no
significant association was found between s-CEA and
OS in patients with Stage III disease (Kaplan Meier
curves displayed in Additional file 1, Figure S1).
There was a significant association between high
s-TATI levels and a reduced DFS in Stage III patients
(Figure 4), also confirmed in Cox univariate analysis
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(HR = 1.80; 95% CI 1.05-3.07, P = 0.033) but not in
multivariate analysis (data not shown). In Stage II
patients there was no significant association between
s-TATI and DFS (Figure 4). S-CEA had no impact on
DFS when analyzed separately for patients with Stage II
or Stage III disease (Additional file 1, Figure S1). In
contrast to previous findings regarding t-TATI [3] there
was no relationship between levels of s-TATI and time
to liver or lung metastasis (data not shown).
In patients who had not received preoperative RT,
s-TATI was an independent prognostic factor (HR =
2.52; 95% CI 1.70-3.72, P < 0.001) in univariate analysis
Figure 1 ROC curve analysis. ROC curve analysis calculated with the use of survival data (OS), showing AUC on s-TATI compared to s-CEA in all
patients (A), curatively treated patients (B). Cut-off based on the point farthest to the northwest (black arrow) extracted from ROC curves data
table (data table not shown).
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and HR = 1.97; 95% CI 1.28-2.99, P = 0.002 in multi-
variate analysis). In patients who had received preopera-
tive RT, s-TATI was prognostic in univariate (HR =
2.27; 95% CI 1.21-4.25, P = 0.014) but not multivariate
analysis (data not shown).
Discussion
In this study, we have shown that elevated levels of s-
TATI independently predict an adverse outcome in
CRC patients and this was also the case in separate ana-
lysis of patients with Stage II and III disease.
We have previously shown that high expression of
TATI in tumour tissue correlates with an adverse prog-
nosis in two independent cohorts of CRC patients,
including the cohort studied here, in which t-TATI was
also significantly associated with a reduced time to
metachronous liver metastasis [3]. The lack of any asso-
ciation between s-TATI levels and t-TATI is therefore
somewhat surprising, given the significant relationship
between s-TATI and an adverse prognosis demonstrated
in this study. Indeed, s-TATI and t-TATI remained
independent prognostic factors when both were
included in multivariate analysis. In addition, while
s-TATI levels were significantly higher in patients pre-
senting with distant metastasis at diagnosis, we could
not confirm any relationship between s-TATI and time
to liver or lung metastases.
To our knowledge, the relationship between s-TATI
and t-TATI has only been investigated in one previous
study on renal cell carcinoma, which also failed to show
a significant association between these variables [21].
However, in that study, it was also shown that an
impaired renal function could contribute to elevated
s-TATI levels in patients with renal cancer. A limitation
to this study is the lack of information on renal function
for the patients included. The relationship between
s-TATI and renal function in CRC patients is an impor-
tant issue that should be addressed in future studies. In
Figure 2 Distribution of s-TATI according to disease stage. Box plots displaying s-TATI distribution in TNM Stage and subcategories. Boxes
show 25th, 50th, 75th percentiles, whiskers show 5th and 95th percentile. Outliers are represented with circles while black dots represent extreme
outliers. Distribution of s-TATI according to TNM stage (A), tumour stage (B), nodal stage (C) and metastatic stage (D). Kruskal Wallis test was
used for statistical analysis.
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Table 1 Correlation between TATI serum levels and clinicopathological characteristics
Categories calculated via ROC-curve: < 15.59 > 15.59 total P-value missing
Ranges (s-TATI μg/l) 4.346-15.587 15.588-168.570
n(%) 192(59.3) 132(40.7) 324(100)
Age
< 75 129(69.7) 50(40.7) 179(58.1)
≥75 56(30.3) 73(59.3) 129(41.9) < 0.001** 16(4.9)
Gender
Female 90(46.9) 71(53.8) 161(49.7)
Male 102(53.1) 61(46.2) 163(50.3) 0.289 0(0.0)
Disease stage
I 26(13.7) 18(13.8) 44(13.8)
II 84(44.2) 50(38.5) 134(41.9)
III 58(30.5) 37(28.5) 95(29.7)
IV 22(11.6) 25(19.2) 47(14.7) 0.284 4(1.2)
Differentiation grade
High-moderate 155(80.7) 95(74.2) 250(78.1)
Poor 37(19.3) 33(25.8) 70(21.9) 0.168 4(1.2)
Vascular invasion
No invasion 164(88.6) 106(86.2) 270(87.7)
Invasion 21(11.4) 17(13.8) 38(12.3) 0.519 16(4.9)
Mucinous or non-mucinous
Non mucinous tumour 161(87.0) 106(86.2) 267(86.7)
Mucinous tumour 24(13.0) 17(13.8) 41(13.3) 0.830 16(4.9)
Colon or rectal cancer
Colon cancer 115(59.6) 102(77.9) 217(67.0)
Rectal cancer 78(40.4) 29(22.1) 107(33.0) 0.001 0(0)
Colon left or right ex ca recti
Right colon 58(50.4) 64(63.4) 122(56.2)
Left colon 57(49.6) 37(36.6) 94(43.5) 0.056 1(0.5)
CEA serum
< 2,67 μg/L 101(52.6) 57(43.2) 158(48.8)
≥ 2,67 μg/L 91(47.4) 75(56.8) 166(51.2) 0.095 0(0)
Preop radiation therapy
Received 129(66.8) 110(84.0) 239(73.8)
Not received 64(33.2) 21(16.0) 85(26.2) 0.001 0(0)
TATI expression in tissue
< 50% 145(81.0) 87(73.7) 232(78.1)
≥ 50% 34(19.0) 31(26.3) 65(21.9) 0.138 27(8.3)
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this study, age at diagnosis was significantly associated
with high s-TATI levels, which is in line with the study
by Solakidi et al. [15]. As high age is associated with a
poor DFS and OS in CRC, and also with an impaired
renal function, this relationship could to some extent
contribute to the adverse prognostic impact of high
s-TATI levels. Notably, the independent prognostic
value of s-TATI remained significant for both DFS and
OS when adjusted for age in the multivariate Cox
regression analysis.
Elevation of s-TATI may also be caused by several non-
malignant conditions such as severe inflammatory disease
[22], pancreatitis and hepatobiliary disease [23], and tis-
sue destruction [24,25]. TATI is produced at high con-
centration in the pancreas, from which it leaks into
serum in pancreatic disease [24]. However, normal s-
TATI levels have been found after total pancreatectomy
showing that TATI is produced in several tissues [26,27].
Solakidi et al suggested that leakage from the tumour
cells into the circulation might be the mechanism behind
elevated s-TATI levels [15], but the lack of a correlation
between s-TATI and t-TATI in this study implies that
leakage from the tumour into the circulation is not a
major cause of elevated s-TATI levels. Apart from its
trypsin inhibiting function, TATI has also been ascribed
properties promoting a more malignant phenotype in
CRC [4] and in prostate cancer cells [28]. Interestingly,
TATI has been shown to stimulate the EGF receptor and
thus increase tumour aggressiveness [29]. Therefore, it
could well be that t-TATI contributes to the biological
aggressiveness of the tumour per se, whereas s-TATI
levels reflect a local and/or systemic response to the
disease.
Notably, while there was no association between
t-TATI and tumour location, s-TATI levels were signifi-
cantly lower in left-sided tumours compared to right-
sided tumours and in rectal cancers compared to
colonic cancers, the majority of which had received pre-
operative RT. None of these associations were seen for
s-CEA. The significant association between lower
Figure 3 Prognostic value of s-TATI in all patients. Kaplan Meier estimates of disease free survival and overall survival in strata of s-TATI levels
according to the cut-off derived from the ROC analysis (A, C) and quartiles (B, D).
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s-TATI levels and RT indicates that treatment might
directly affect s-TATI levels. This would be of interest
to investigate in future studies, comparing levels of
s-TATI before, during and after RT. In this study,
s-TATI was an independent prognostic factor in
patients not receiving RT, whereas it was only prognos-
tic in univariate analysis in patients treated with RT. As
the number of patients that had received RT was rela-
tively small (n = 85) and the number of patients that
had not received RT was even smaller (n = 23), no con-
clusions can be drawn regarding the value of s-TATI as
a predictor of response to preoperative RT in rectal can-
cer patients. This should be investigated in a prospective
setting, preferably a randomised trial.
Notably, the significantly lower s-TATI levels in left-
sided compared to right-sided colonic tumours indicate
that differences in s-TATI levels according to tumour
location might also be due to differences in biological
characteristics of the tumours, e.g., microsatellite
instability (MSI), which is more frequently present in
tumours arising in the right colon [30,31]. Information
on MSI status was not available for the tumours in this
study, but should be considered in future studies.
Earlier studies on s-TATI in colorectal cancer have
only concerned its diagnostic value, and for this purpose
s-TATI has not been found to provide information addi-
tional to that obtained with s-CEA [13,14]. The prog-
nostic value of s-TATI in CRC has not been studied
before. In the present study s-TATI was found to be a
prognostic biomarker that was independent of conven-
tional clinicopathological factors, and also independent
of s-CEA. Furthermore, in most settings, the value of
s-TATI was stronger than that of s-CEA.
Individualised treatment is still not available for
patients with CRC in the adjuvant setting; currently the
TNM stage is used for selection of patients for adjuvant
treatment. In stage II patients about 20% will develop
cancer recurrence, and there is modest evidence that
Table 2 Cox univariate and multivariate analysis of the relative risks for death and recurrent disease according to
TATI serum levels
Relative risk for death in all
patients
(Overall survival)
Relative risk for second cancer, recurrence or death to any cause in curatively
treated patients
(Disease free survival)
Univariate Multivariate Univariate Multivariate
n* HR (95% CI) HR (95% CI) n HR (95% CI) HR (95% CI)
Age at operation
Age <75 years 180 1.0 (ref) 1.0 (ref) 148 1.0 (ref) 1.0 (ref)
Age ≥75 years 129 1.88(1.34-2.62) 2.23(1.55-3.23) 116 2.00(1.39-2.86) 1.94(1.30-2.87)
Gender
Female 161 1.0 (ref) 1.0 (ref) 134 1.0 (ref) 1.0 (ref)
Male 164 0.86(0.62-1.18) 0.82(0.58-1.16) 136 0.84(0.59-1.20) 0.82(0.57-1.19)
Disease stage
Stage I 44 1.0 (ref) 1.0 (ref) 44 1.0 (ref) 1.0 (ref)
Stage II 134 0.95(0.52-1.74) 1.07(0.57-2.01) 132 1.36(0.75-2.45) 1.47(0.79-2.70)
Stage III 96 1.84(1.02-3.34) 1.94(1.04-3.65) 92 2.25(1.25-4.06) 2.27(1.21-4.24)
Stage IV 47 7.62(4.11-14.16) 6.88(3.43-13.82) 0 N/A N/A
Differentiation grade
High-moderate 251 1.0 (ref) 1.0 (ref) 215 1.0 (ref) 1.0 (ref)
Poor 70 1.55(1.07-2.25) 1.38(0.92-2.07) 55 1.31(0.86-2.00) 1.31(0.85-2.02)
Vascular invasion
No invasion 271 1.0 (ref) 1.0 (ref) 243 1.0 (ref) 1.0 (ref)
Invasion 38 2.24(1.45-3.46) 1.29(0.80-2.08) 21 1.67(0.94-2.98) 1.52(0.83-2.78)
s-CEA
< 2,67 μg/L 159 1.0 (ref) 1.0 (ref) 146 1.0 (ref) 1.0 (ref)
≥2,67 μg/L 165 2.05(1.47-2.87) 1.60(1.11-2.32) 124 1.56(1.10-2.23) 1.59(1.10-2.32)
s-TATI
< 15,59 μg/L 159 1.0 (ref) 1.0 (ref) 165 1.0 (ref) 1.0 (ref)
≥15,59 μg/L 165 2.40(1.74-3.33) 1.78(1.25-2.53) 105 2.00(1.40-2.84) 1.51(1.03-2.22)
t-TATI
≤50% cells 233 1.0 (ref) 1.0 (ref) 196 1.0 (ref) 1.0 (ref)
> 50% cells 65 1.40(0.96-2.05) 1.25(0.85-1.86) 58 1.67(1.12-2.49) 1.56(1.04-2.34)
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these patients benefit from adjuvant chemotherapy [32].
Several high risk factors have been suggested for select-
ing stage II patients for adjuvant chemotherapy, i.e few
lymph nodes examined, T4 disease, obstruction and
tumour perforation [33]. Stage III CRC patients, on the
other hand, have a well documented benefit from adju-
vant chemotherapy [34] although it is estimated that up
to 80% will relapse despite adjuvant treatment. It is
therefore obvious that more accurate prognostic factors
are needed when selecting patients for adjuvant treat-
ment in CRC. The data presented here show that s-
TATI is an independent prognostic biomarker in the
whole cohort and in separate analysis of patients with
Stage II and III disease.
Conclusions
In summary, we have demonstrated that TATI in serum,
although not associated with its tumour-specific
expression in tissue, is an independent predictor of a
poor outcome in CRC patients. As this was evident in
separate analysis of Stage II and Stage III patients, the
prognostic value of s-TATI should be studied further to
clarify whether it can be used as a biomarker for deci-
sion making regarding the benefit from adjuvant che-
motherapy in patients with Stage II disease and the
intensity of adjuvant chemotherapy needed in patients
with Stage III disease.
Additional material
Additional file 1: Prognostic impact of s-CEA in Stage II and Stage
III disease. Kaplan Meier estimates of disease free survival according to
high and low s-CEA levels derived from ROC-analysis in Stage II (A) and
Stage III patients (B), and overall survival in Stage II (C) and Stage III
patients (D), respectively.
Figure 4 Prognostic impact of s-TATI in Stage II and Stage III disease. Kaplan Meier estimates of disease free survival according to high and
low s-TATI levels derived from ROC-analysis in Stage II (A) and Stage III patients (B), and overall survival in Stage II (C) and Stage III patients (D),
respectively.
Gaber et al. BMC Cancer 2010, 10:498
http://www.biomedcentral.com/1471-2407/10/498
Page 9 of 11
Acknowledgements
This work was supported by grants from the Swedish Cancer Society, the
Knut and Alice Wallenberg Foundation, Gunnar Nilsson’s Cancer Foundation,
the Research Funds of Malmö University Hospital, the Crafoord foundation,
the Research Fund of the County of Västmanland Against Cancer, Lions
Cancer Foundation Uppsala.
Author details
1Center for Molecular Pathology, Department of Laboratory Medicine, Lund
University, Skåne University Hospital, Malmö, Sweden. 2Department of
Clinical Chemistry, University of Helsinki and Helsinki University Central
Hospital, Helsinki, Finland. 3Department of Clinical Sciences, Division of
Urological Cancers, Lund University, Skåne University Hospital, Malmö,
Sweden. 4Department of Surgery, University of Uppsala, Uppsala, Sweden.
Authors’ contributions
AG participated in the collection of data, performed statistical analyses and
drafted the manuscript. BN assisted with the serum analyses and revision of
the manuscript. EN assisted with the serum analyses. KH performed the
serum analyses and revised the manuscript. UHS participated in the design
of the study and helped with revision of the manuscript. AB participated in
the design of the study and helped with the revision of the manuscript. HB
included the patients into the study, collected data, drafted the manuscript
and participated in the statistical analysis. KJ participated in the conception
and design of the study, statistical analysis, drafted and revised the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 April 2010 Accepted: 17 September 2010
Published: 17 September 2010
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55(2):74-108.
2. Iqbal S, Stoehlmacher J, Lenz HJ: Tailored chemotherapy for colorectal
cancer: a new approach to therapy. Cancer Invest 2004, 22(5):762-773.
3. Gaber A, Johansson M, Stenman UH, Hotakainen K, Ponten F, Glimelius B,
Bjartell A, Jirstrom K, Birgisson H: High expression of tumour-associated
trypsin inhibitor correlates with liver metastasis and poor prognosis in
colorectal cancer. British journal of cancer 2009, 100(10):1540-1548.
4. Gouyer V, Fontaine D, Dumont P, de Wever O, Fontayne-Devaud H,
Leteurtre E, Truant S, Delacour D, Drobecq H, Kerckaert JP, et al: Autocrine
induction of invasion and metastasis by tumor-associated trypsin
inhibitor in human colon cancer cells. Oncogene 2008, 27(29):4024-4033.
5. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M, Ylikorkala O:
Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a
preoperative prognostic indicator in advanced ovarian cancer. British
journal of cancer 1994, 70(6):1188-1190.
6. Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A,
Wahlstrom T, Stenman UH: Expression of trypsinogen-1, trypsinogen-2,
and tumor-associated trypsin inhibitor in ovarian cancer: prognostic
study on tissue and serum. Clin Cancer Res 2004, 10(14):4761-4768.
7. Pectasides D, Bafaloucos D, Antoniou F, Gogou L, Economides N,
Varthalitis J, Dimitriades M, Kosmidis P, Athanassiou A: TPA, TATI, CEA, AFP,
beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell
carcinoma of the bladder. Am J Clin Oncol 1996, 19(3):271-277.
8. Kelloniemi E, Rintala E, Finne P, Stenman UH: Tumor-associated trypsin
inhibitor as a prognostic factor during follow-up of bladder cancer.
Urology 2003, 62(2):249-253.
9. Paju A, Jacobsen J, Rasmuson T, Stenman UH, Ljungberg B: Tumor
associated trypsin inhibitor as a prognostic factor in renal cell
carcinoma. The Journal of urology 2001, 165(3):959-962.
10. Meria P, Toubert ME, Cussenot O, Bassi S, Janssen T, Desgrandchamps F,
Cortesse A, Schlageter MH, Teillac P, Le Duc A: Tumour-associated trypsin
inhibitor and renal cell carcinoma. European urology 1995, 27(3):223-226.
11. Taccone W, Mazzon W, Belli M: Evaluation of TATI and other markers in
solid tumors. Scandinavian journal of clinical and laboratory investigation
1991, 207:25-32.
12. Satake K, Inui A, Sogabe T, Yoshii Y, Nakata B, Tanaka H, Chung YS, Hiura A,
Umeyama K: The measurement of serum immunoreactive pancreatic
secretory trypsin inhibitor in gastrointestinal cancer and pancreatic
disease. Int J Pancreatol 1988, 3(5):323-331.
13. Pasanen P, Eskelinen M, Kulju A, Penttila I, Janatuinen E, Alhava E: Tumour-
associated trypsin inhibitor (TATI) in patients with colorectal cancer: a
comparison with CEA, CA 50 and CA 242. Scand J Clin Lab Invest 1995,
55(2):119-124.
14. Catarino M, Conde R: Tumor-associated trypsin inhibitor (TATI) in patients
with colorectal carcinoma. A critical comparison with CEA. Scandinavian
journal of clinical and laboratory investigation 1991, 207:43-46.
15. Solakidi S, Dessypris A, Stathopoulos GP, Androulakis G, Sekeris CE: Tumour-
associated trypsin inhibitor, carcinoembryonic antigen and acute-phase
reactant proteins CRP and alpha1-antitrypsin in patients with
gastrointestinal malignancies. Clin Biochem 2004, 37(1):56-60.
16. Stenman UH, Koivunen E, Itkonen O: Biology and function of tumor-
associated trypsin inhibitor, TATI. Scandinavian journal of clinical and
laboratory investigation 1991, 207:5-9.
17. Matsuda K, Ogawa M, Shibata T, Nishibe S, Miyauchi K, Matsuda Y, Mori T:
Postoperative elevation of serum pancreatic secretory trypsin inhibitor.
Am J Gastroenterol 1985, 80(9):694-698.
18. Eddeland A, Ohlsson K: A radioimmunoassay for measurement of human
pancreatic secretory trypsin inhibitor in different body fluids. Hoppe-
Seyler’s Zeitschrift fur physiologische Chemie 1978, 359(6):671-675.
19. Ogawa M: Pancreatic secretory trypsin inhibitor as an acute phase
reactant. Clin Biochem 1988, 21(1):19-25.
20. Punt CJ, Köhne Claus-Henning, Hohenberger Peter, Labianca Roberto,
Hans JSchmoll, Påhlman Lars, Alberto Sobrero J-YD: Endpoints in Adjuvant
Treatment Trials: A Systematic Review of the Literature in Colon Cancer
and Proposed Definitions for Future Trials. J Natl Cancer Inst 2007,
99:998-1003.
21. Lukkonen A, Lintula S, von Boguslawski K, Carpen O, Ljungberg B,
Landberg G, Stenman UH: Tumor-associated trypsin inhibitor in normal
and malignant renal tissue and in serum of renal-cell carcinoma
patients. Int J Cancer 1999, 83(4):486-490.
22. Huhtala ML, Kahanpaa K, Seppala M, Halila H, Stenman UH: Excretion of a
tumor-associated trypsin inhibitor (TATI) in urine of patients with
gynecological malignancy. Int J Cancer 1983, 31(6):711-714.
23. Haglund C, Huhtala ML, Halila H, Nordling S, Roberts PJ, Scheinin TM,
Stenman UH: Tumour-associated trypsin inhibitor, TATI, in patients with
pancreatic cancer, pancreatitis and benign biliary diseases. British journal
of cancer 1986, 54(2):297-303.
24. Hedstrom J, Haglund C, Leinonen J, Nordling S, Stenman UH: Trypsinogen-
1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract
tissues from patients with biliary tract diseases and pancreatic
carcinomas. Scand J Clin Lab Invest 2001, 61(2):111-118.
25. Ogawa M, Matsuda K, Shibata T, Matsuda Y, Ukai T, Ohta M, Mori T:
Elevation of serum pancreatic secretory trypsin inhibitor (PSTI) in
patients with serious injury. Res Commun Chem Pathol Pharmacol 1985,
50(2):259-266.
26. Lasson A, Borgstrom A, Ohlsson K: Serum levels of immunoreactive PSTI
in acute abdominal disorders, with special reference to a possible
extrapancreatic PSTI production. Clin Chim Acta 1986, 161(1):37-46.
27. Halila H, Huhtala ML, Schroder T, Kiviluoto T, Stenman UH: Pancreatic
secretory trypsin inhibitor-like immunoreactivity in pancreatectomized
patients. Clin Chim Acta 1985, 153(3):209-216.
28. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F,
Helgeson BE, Laxman B, Morris DS, et al: The role of SPINK1 in ETS
rearrangement-negative prostate cancers. Cancer cell 2008, 13(6):519-528.
29. Ozaki N, Ohmuraya M, Hirota M, Ida S, Wang J, Takamori H, Higashiyama S,
Baba H, Yamamura K: Serine protease inhibitor Kazal type 1 promotes
proliferation of pancreatic cancer cells through the epidermal growth
factor receptor. Mol Cancer Res 2009, 7(9):1572-1581.
30. Miyakura Y, Sugano K, Konishi F, Ichikawa A, Maekawa M, Shitoh K,
Igarashi S, Kotake K, Koyama Y, Nagai H: Extensive methylation of hMLH1
promoter region predominates in proximal colon cancer with
microsatellite instability. Gastroenterology 2001, 121(6):1300-1309.
31. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O’Connor T,
Ward R: CpG island methylation in sporadic colorectal cancers and its
Gaber et al. BMC Cancer 2010, 10:498
http://www.biomedcentral.com/1471-2407/10/498
Page 10 of 11
relationship to microsatellite instability. Gastroenterology 2002,
122(5):1376-1387.
32. Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK,
Williams NS, Kerr DJ: Adjuvant chemotherapy versus observation in
patients with colorectal cancer: a randomised study. Lancet 2007,
370(9604):2020-2029.
33. Figueredo A, Coombes ME, Mukherjee S: Adjuvant therapy for completely
resected stage II colon cancer. Cochrane Database Syst Rev 2008, , 3:
CD005390.
34. Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y,
Green E, Labianca R, O’Callaghan C, et al: Evidence for cure by adjuvant
therapy in colon cancer: observations based on individual patient data
from 20,898 patients on 18 randomized trials. J Clin Oncol 2009,
27(6):872-877.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/498/prepub
doi:10.1186/1471-2407-10-498
Cite this article as: Gaber et al.: Increased serum levels of tumour-
associated trypsin inhibitor independently predict a poor prognosis in
colorectal cancer patients. BMC Cancer 2010 10:498.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gaber et al. BMC Cancer 2010, 10:498
http://www.biomedcentral.com/1471-2407/10/498
Page 11 of 11
